Article Versions Notes

Cicala G, Russo G, Santoro V, Franchina T, Silvestris N, Santarpia M, Spina E, Barbieri MA. Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System. Pharmaceuticals. 2024; 17(10):1266. https://doi.org/10.3390/ph17101266

Cicala, Giuseppe, Giulia Russo, Vincenza Santoro, Tindara Franchina, Nicola Silvestris, Mariacarmela Santarpia, Edoardo Spina, and Maria Antonietta Barbieri. 2024. "Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System" Pharmaceuticals 17, no. 10: 1266. https://doi.org/10.3390/ph17101266

Cicala, G., Russo, G., Santoro, V., Franchina, T., Silvestris, N., Santarpia, M., Spina, E., & Barbieri, M. A. (2024). Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System. Pharmaceuticals, 17(10), 1266. https://doi.org/10.3390/ph17101266